Financials

v3.21.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 11,629 $ 5,413
Receivables 398 884
Inventory 218 328
Prepaid expenses and other current assets 816 522
Discontinued operations - current assets 128 181
Total current assets 13,189 7,328
Property and equipment, net 563 618
Operating lease right-of-use asset 72 141
Total Assets 13,824 8,087
Current liabilities:    
Accounts payable 768 1,253
Accrued clinical trials expenses 151 214
Other accrued liabilities 296 319
Operating lease liability, current 76 150
Current portion of long-term debt 572 327
Discontinued operations - current liabilities 1,893 1,960
Total current liabilities 3,756 4,223
Long-term debt 88 332
Total liabilities 3,844 4,555
Stockholders' equity    
Common stock, at amounts paid-in 10 7
Additional paid-in capital 379,890 370,804
Accumulated deficit (369,920) (367,279)
Total stockholders' equity 9,980 3,532
Total liabilities and stockholders' equity $ 13,824 $ 8,087

Source

v3.21.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Revenue:    
Total revenue $ 682 $ 1,126
Operating expenses:    
Cost of goods sold 110 0
Research and development 1,877 1,812
General and administrative 1,327 1,289
Total operating expenses 3,314 3,101
Loss from operations (2,632) (1,975)
Other expense:    
Interest expense, net (1) (222)
Non-cash loss on changes in the fair value of warrants 0 (923)
Other expense, net (8) (213)
Other expense, net (9) (1,358)
Loss from continuing operations (2,641) (3,333)
Loss on discontinued operations 0 (2,251)
Net loss and comprehensive loss $ (2,641) $ (5,584)
Basic and diluted net loss per common share from continuing operations $ (0.28) $ (1.21)
Basic and diluted net loss per common share on discontinued operations $ 0.00 $ (0.82)
Weighted average shares used in computing basic and diluted net loss per common share 9,289 2,755
License revenue    
Revenue:    
Total revenue $ 2 $ 0
Product revenue    
Revenue:    
Total revenue 111 0
Grant revenue    
Revenue:    
Total revenue $ 569 $ 1,126

Source

v3.21.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities:    
Net loss $ (2,641) $ (5,584)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 55 62
Non-cash interest expense 1 148
Non-cash loss on changes in fair value of warrants 0 923
Stock-based compensation 248 (84)
Finance costs attributable to issuance of warrants 0 211
Other (5) (3)
Changes in operating assets and liabilities:    
Receivables 487 (558)
Inventory 110 (66)
Prepaid expenses and other assets (241) (399)
Accounts payable (482) (64)
Accrued sales allowances (4) (608)
Other accrued liabilities (153) 810
Net cash used in operating activities (2,625) (5,212)
Cash flows from investing activities:    
Purchases of property and equipment 0 (30)
Net cash used in investing activities 0 (30)
Cash flows from financing activities:    
Net proceeds from equity offering 8,841 1,895
Net proceeds from the exercises of common stock warrants 0 6,162
Net cash provided by financing activities 8,841 8,057
Net increase in cash and cash equivalents 6,216 2,815
Cash and cash equivalents at beginning of period 5,413 5,223
Cash and cash equivalents at end of period 11,629 8,038
Supplemental disclosure of cash flow information:    
Interest paid 0 102
Purchases of property and equipment included in accounts payable $ 0 $ 6

Source